96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02255370
(ClinicalTrials.gov)
December 201419/9/2014Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn DiseaseControlled, Randomized, Double Blind Study, Comparing Curcumin to Thiopurines in the Prevention of Post-op Recurrence in Crohn DiseaseCrohn's DiseaseDrug: CurcuminUniversity Hospital, Clermont-Ferrand3i nature;Naturopôle Nutrition santéCompleted18 YearsN/AAll61Phase 3France
2EUCTR2014-000261-51-FR
(EUCTR)
04/11/201428/08/2015Randomized, controlled, double bind study, comparing curcumin to placebo, associated with thiopurines, in the the prevention of post-operative Crohn's desease relapsePOPCUR : a randomized, controlled, double bind study, comparing curcuma to placebo, associated with thiopurines, in the prevention of post-operative Crohn's disease recurrence - POPCUR Crohn's Disease
MedDRA version: 18.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Curcuma
Other descriptive name: CURCUMA LONGA RHIZOMA
CHU de Clermont-FerrandNULLNot RecruitingFemale: yes
Male: yes
122Phase 3France
3JPRN-UMIN000015770
2014/09/0101/12/2014Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease.Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease. Crohn's disease (180 <= CDAI < 450)CDAI: Crohn's disease Activity IndexStandard therapy for Crohn's disease (Pentasa 3 g/day)
Patients take curcumin or placebo
Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease ResearchNULLComplete: follow-up complete20years-old70years-oldMale and Female30Not selectedJapan
4NCT00889161
(ClinicalTrials.gov)
May 200924/4/2009Curcumin in Pediatric Inflammatory Bowel DiseaseCurcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration StudyInflammatory Bowel Disease;Ulcerative Colitis;Crohn's DiseaseDrug: CurcuminSeattle Children's HospitalNULLCompleted8 Years18 YearsBoth11Phase 1United States